Trandolapril

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

群多普利是一种口服血管紧张素转换酶 (ACE) 抑制剂，可水解为活性二酸群多普利拉。

Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that is hydrolysed to the active diacid trandolaprilat.

Trandolapril (0.02 mM, 1 mM; 3 d) inhibits cell growth and induces cell apoptosis, increases the percentage of apoptotic cells in K562 cell line. Apoptosis Analysis Cell Line:K562, KU812, U937 and HL60 Concentration:0-2 mM Incubation Time:0, 1, 2, 3 days Result:Inhibited K562, KU812, U937 at 1 mM and inhibited HL60 at 0.02 mM.

Trandolapril (3 mg/kg/day; p.o.; 7 d) reduces renal fibrosis in obstructive nephropathy in mice, by inhibiting renal interstitial matrix expression and myofibroblast activation, decreasing renal proinflammatory cytokine RANTES and TNF-α level.Trandolapril (0.3 mg/kg/day; p.o.; 4 weeks) improves arterial mechanics in rats, prevents arterial hypertrophy, collagen and cellular fibronectin accumulation.randolapril (0.3 mg/kg/day; p.o.; 4 months) exhibits a chronic anti-hypertension effects in rats, results in blood pressure decreasing.Trandolapril (0.25 mg/kg; p.o.; twice a day; 4 months) inhibits Atherosclerosis in the Watanabe Heritable Hyperlipidemic Rabbit. Animal Model:UUD (unilateral ureteral obstruction) model in Male CD-1 mice (18-22 g) Dosage:3 mg/kg Administration:Oral gavage; daily, for 7 days Result:Resulted in renal interstitial matrix expression (including fibronectin, type I, and type III collagen) decreasing, and inhibited myofibroblast activation by surprising a-smooth muscle actin (a-SMA) expression, decreased the RANTES (regulated on activation, normal T cell expressed and secreted) and TNF-α level.Animal Model:SHR model (spontaneously hypertensive rats, 4-week-old) Dosage:0.3 mg/kg Administration:Oral gavage; daily for 4 weeks Result:Reduced collagen content in the aortic media and increased ariterial distensibility up to about 80%.Animal Model:Watanabe heritable hyperlipidemic rabbit (3 months old)Dosage:0.25 mg/kg Administration:Oral gavage; twice a day; 9 months Result:Decreased in atherosclerotic involvement of the intimal surface, and also decreased cholesterol content in descending thoracic aorta.

RU44570

Metabolic Enzyme/Protease

ACE

——

——

——

87679-37-6

430.545

C24H34N2O5

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (232.27 mM)

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years